Cargando…

The Expression Profile, Clinical Application and Potential Tumor Suppressing Mechanism of hsa_circ_0001675 in Head and Neck Carcinoma

PURPOSE: This study sought to identify circular RNAs (circRNA) that participate in the regulation of head and neck cancer (HNC), analyze their clinical application, and predict their molecular mechanism during HNC. MATERIALS AND METHODS: High-throughput sequencing was used to analyze circRNA express...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Yujie, Ye, Dong, Shen, Zhisen, Li, Zan, Li, Qun, Rong, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121769/
https://www.ncbi.nlm.nih.gov/pubmed/35600372
http://dx.doi.org/10.3389/fonc.2022.769666
_version_ 1784711219424264192
author Cao, Yujie
Ye, Dong
Shen, Zhisen
Li, Zan
Li, Qun
Rong, Hao
author_facet Cao, Yujie
Ye, Dong
Shen, Zhisen
Li, Zan
Li, Qun
Rong, Hao
author_sort Cao, Yujie
collection PubMed
description PURPOSE: This study sought to identify circular RNAs (circRNA) that participate in the regulation of head and neck cancer (HNC), analyze their clinical application, and predict their molecular mechanism during HNC. MATERIALS AND METHODS: High-throughput sequencing was used to analyze circRNA expression in 18 matched HNC and adjacent normal tissues. Target circRNAs with significantly differential expression were obtained. In 103 HNC and adjacent normal tissues, real-time fluorescent quantitative PCR (qRT-PCR) was used to verify the differential expression of target circRNAs. This data was combined with clinicopathological information to analyze the diagnostic value of target circRNA. Bioinformatics was used to find target circRNAs that acted as competitive endogenous RNA (ceRNA) and construct a circRNA-miRNA-mRNA regulatory network. mRNA expression was verified by immunohistochemistry (IHC). RESULTS: A total of 714 differentially expressed circRNAs were detected in HNC, and the low expression of hsa_circ_0001675 was particularly significant (fold change [FC] = -4.85, P = 6.305E-05). hsa_circ_0001675 had significantly lower expression in HNC than in normal tissue (P < 0.01). Low hsa_circ_0001675 expression was positively associated with tumor invasion and clinical staging (P < 0.05), and its area under the ROC curve (AUC) was 0.7776. Low hsa_circ_0001675 expression also correlated with the overall survival (OS) rate and the progression-free survival (PFS) rate of HNC patients (P < 0.001). Bioinformatics was used to construct a ceRNA network of hsa_circ_0001675 with six differentially expressed miRNAs (hsa-miR-330-5p, hsa-miR-498, hsa-miR-532-3p, hsa-miR-577, hsa-miR-1248, and hsa-miR-1305) and 411 differentially expressed mRNAs and found that the neuroactive ligand-receptor interaction, and the cAMP and calcium signaling pathways were particularly enriched. Further bioinformatics and IHC analysis showed that miR577/TESC is the likely downstream signaling pathway for hsa_circ_0001675. CONCLUSION: This study showed that hsa_circ_0001675 is downregulated in HNC and could be an effective biomarker for HNC diagnosis. In addition, hsa_circ_0001675 may have a potential ceRNA mechanism and suppress HNC disease progression through the hsa_circ_0001675-miRNA-mRNA axis.
format Online
Article
Text
id pubmed-9121769
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91217692022-05-21 The Expression Profile, Clinical Application and Potential Tumor Suppressing Mechanism of hsa_circ_0001675 in Head and Neck Carcinoma Cao, Yujie Ye, Dong Shen, Zhisen Li, Zan Li, Qun Rong, Hao Front Oncol Oncology PURPOSE: This study sought to identify circular RNAs (circRNA) that participate in the regulation of head and neck cancer (HNC), analyze their clinical application, and predict their molecular mechanism during HNC. MATERIALS AND METHODS: High-throughput sequencing was used to analyze circRNA expression in 18 matched HNC and adjacent normal tissues. Target circRNAs with significantly differential expression were obtained. In 103 HNC and adjacent normal tissues, real-time fluorescent quantitative PCR (qRT-PCR) was used to verify the differential expression of target circRNAs. This data was combined with clinicopathological information to analyze the diagnostic value of target circRNA. Bioinformatics was used to find target circRNAs that acted as competitive endogenous RNA (ceRNA) and construct a circRNA-miRNA-mRNA regulatory network. mRNA expression was verified by immunohistochemistry (IHC). RESULTS: A total of 714 differentially expressed circRNAs were detected in HNC, and the low expression of hsa_circ_0001675 was particularly significant (fold change [FC] = -4.85, P = 6.305E-05). hsa_circ_0001675 had significantly lower expression in HNC than in normal tissue (P < 0.01). Low hsa_circ_0001675 expression was positively associated with tumor invasion and clinical staging (P < 0.05), and its area under the ROC curve (AUC) was 0.7776. Low hsa_circ_0001675 expression also correlated with the overall survival (OS) rate and the progression-free survival (PFS) rate of HNC patients (P < 0.001). Bioinformatics was used to construct a ceRNA network of hsa_circ_0001675 with six differentially expressed miRNAs (hsa-miR-330-5p, hsa-miR-498, hsa-miR-532-3p, hsa-miR-577, hsa-miR-1248, and hsa-miR-1305) and 411 differentially expressed mRNAs and found that the neuroactive ligand-receptor interaction, and the cAMP and calcium signaling pathways were particularly enriched. Further bioinformatics and IHC analysis showed that miR577/TESC is the likely downstream signaling pathway for hsa_circ_0001675. CONCLUSION: This study showed that hsa_circ_0001675 is downregulated in HNC and could be an effective biomarker for HNC diagnosis. In addition, hsa_circ_0001675 may have a potential ceRNA mechanism and suppress HNC disease progression through the hsa_circ_0001675-miRNA-mRNA axis. Frontiers Media S.A. 2022-05-06 /pmc/articles/PMC9121769/ /pubmed/35600372 http://dx.doi.org/10.3389/fonc.2022.769666 Text en Copyright © 2022 Cao, Ye, Shen, Li, Li and Rong https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Cao, Yujie
Ye, Dong
Shen, Zhisen
Li, Zan
Li, Qun
Rong, Hao
The Expression Profile, Clinical Application and Potential Tumor Suppressing Mechanism of hsa_circ_0001675 in Head and Neck Carcinoma
title The Expression Profile, Clinical Application and Potential Tumor Suppressing Mechanism of hsa_circ_0001675 in Head and Neck Carcinoma
title_full The Expression Profile, Clinical Application and Potential Tumor Suppressing Mechanism of hsa_circ_0001675 in Head and Neck Carcinoma
title_fullStr The Expression Profile, Clinical Application and Potential Tumor Suppressing Mechanism of hsa_circ_0001675 in Head and Neck Carcinoma
title_full_unstemmed The Expression Profile, Clinical Application and Potential Tumor Suppressing Mechanism of hsa_circ_0001675 in Head and Neck Carcinoma
title_short The Expression Profile, Clinical Application and Potential Tumor Suppressing Mechanism of hsa_circ_0001675 in Head and Neck Carcinoma
title_sort expression profile, clinical application and potential tumor suppressing mechanism of hsa_circ_0001675 in head and neck carcinoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121769/
https://www.ncbi.nlm.nih.gov/pubmed/35600372
http://dx.doi.org/10.3389/fonc.2022.769666
work_keys_str_mv AT caoyujie theexpressionprofileclinicalapplicationandpotentialtumorsuppressingmechanismofhsacirc0001675inheadandneckcarcinoma
AT yedong theexpressionprofileclinicalapplicationandpotentialtumorsuppressingmechanismofhsacirc0001675inheadandneckcarcinoma
AT shenzhisen theexpressionprofileclinicalapplicationandpotentialtumorsuppressingmechanismofhsacirc0001675inheadandneckcarcinoma
AT lizan theexpressionprofileclinicalapplicationandpotentialtumorsuppressingmechanismofhsacirc0001675inheadandneckcarcinoma
AT liqun theexpressionprofileclinicalapplicationandpotentialtumorsuppressingmechanismofhsacirc0001675inheadandneckcarcinoma
AT ronghao theexpressionprofileclinicalapplicationandpotentialtumorsuppressingmechanismofhsacirc0001675inheadandneckcarcinoma
AT caoyujie expressionprofileclinicalapplicationandpotentialtumorsuppressingmechanismofhsacirc0001675inheadandneckcarcinoma
AT yedong expressionprofileclinicalapplicationandpotentialtumorsuppressingmechanismofhsacirc0001675inheadandneckcarcinoma
AT shenzhisen expressionprofileclinicalapplicationandpotentialtumorsuppressingmechanismofhsacirc0001675inheadandneckcarcinoma
AT lizan expressionprofileclinicalapplicationandpotentialtumorsuppressingmechanismofhsacirc0001675inheadandneckcarcinoma
AT liqun expressionprofileclinicalapplicationandpotentialtumorsuppressingmechanismofhsacirc0001675inheadandneckcarcinoma
AT ronghao expressionprofileclinicalapplicationandpotentialtumorsuppressingmechanismofhsacirc0001675inheadandneckcarcinoma